Patent · US Active

Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts

US8614216B2 · kind B2 · utility

6Cited by

44References

27Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Augustus O. Okhamafe · Concord, US
Joyce Chou · Fremont, US
Rampurna Gullapalli · San Bruno, US
Eric Harwood · Seattle, US
David Ryckman · Emeryville, US
Shuguang Zhu · Seattle, US
Xiao Shang · Bellevue, US

Key dates

Filing date	Apr 27, 2012
Grant date	Dec 24, 2013
Priority date	—
Expiry date	Apr 27, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.